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Objectives. We sought to determine prospectively the preva-
lence, evolution and embolic risk of valve excrescences in normal
subjects and patients with and without suspected cardioembolism.
Background. Valve excrescences detected by transesophageal
echocardiography (TEE) have been considered a cardioembolic
substrate in selected patients.
Methods. Ninety healthy volunteers (Group I) and 88 patients
without suspected cardioembolism and a normal TEE (Group II)
were studied and followed up clinically for 58 6 21 and 48 6 20
months, respectively. To assess the evolution of valve excres-
cences, 45 of these subjects underwent repeat TEE at 31 6 13
months. The findings in Groups I and II were compared with
those of Group III—49 patients referred for TEE for suspected
cardioembolism.
Results. Valve excrescences were detected in 34 subjects (38%)
in Group I and in 41 patients (47%) in Group II. In Group III, 20
patients (41%) had excrescences, but 85% of them had other
potential cardiac or vascular sources of embolism. In all groups,
mitral valve excrescences were predominant (68% to 76%), fol-
lowed by aortic (38% to 50%) and right-sided valves (<10%).
Excrescences were equally frequent in men and women and
between all age groups studied. During follow-up in Groups I and
II, excrescences persisted unchanged, and 1 (1.4%) of 74 patients
with and 2 (2%) of 99 subjects without excrescences had cerebral
ischemic events (80% power to detect a clinically meaningful
difference of 4%).
Conclusions. Valve excrescences are common on the left-sided
heart valves of normal subjects and patients regardless of gender
and age; they persist unchanged over time and do not appear to be
a primary source of cardioembolism.
(J Am Coll Cardiol 1997;30:1308–14)
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Valve excrescences have been reported with a frequency of up
to 22% in patients with suspected cardioembolism referred for
transesophageal echocardiography (TEE) (1–4). This finding
has led to the hypothesis that they are a substrate for embo-
lism. However, current data are based on studies of patients
.60 years old in whom cardiac and vascular diseases and
consequently strokes are common. In these groups, it is
frequently difficult to define the etiology of strokes as cardio-
embolic, vasculoembolic or thrombotic (5,6).
If valve excrescences cause cardioembolism, the incidence
of systemic embolism in patients with valve excrescences, but
no other embolic substrate, should be higher than in those
without them. Also, the prevalence of valve excrescences
should be higher in patients with compared with those without
suspected cardioembolism.
Thus, we designed the present study with two objectives: 1)
to determine prospectively the prevalence, evolution and em-
bolic risk of valve excrescences in subjects #60 years old with
no other embolic substrate on TEE; and 2) to determine the
prevalence of valve excrescences in patients with suspected
cardioembolism.
Methods
Study groups. From 1989 to 1996 at the Echocardiography
Laboratory of the Albuquerque Veterans Affairs Medical
Center, a total of 1,352 patients underwent TEE and 454 of
them (34%) were #60 years old. Of these 454 subjects, 178
(39%) had normal TEE studies—90 were healthy volunteers
(Group I) and 88 were patients undergoing TEE for reasons
other than suspected cardioembolism (Group II; 73 were also
in a study of connective tissue diseases). These subjects
underwent TEE as part of prospective studies to assess valve
morphology and function (92%) or to exclude aortic dissection
or congenital heart disease (8%). For comparisons between
Groups I and II, we identified in our computer data base a
total of 49 patients referred for suspected cardioembolism
(Group III) who were in normal sinus rhythm, had no pros-
thetic valves and had no suspected infective endocarditis: 35
had a stroke, 10 had transient ischemic attacks and 4 had a
peripheral embolism. Echocardiography in Group III was
performed 8 6 9 days (range 0 to 29) after the events. The
From the Veterans Affairs Medical Center and University of New Mexico
Health Sciences Center, Albuquerque, New Mexico.
Manuscript received October 18, 1996; revised manuscript received May 30,
1997, accepted July 30, 1997.
Address for correspondence: Dr. Carlos A. Roldan, Cardiology Section
111B, Veterans Affairs Medical Center, 2100 Ridgecrest Drive SE, Albuquerque,
New Mexico 87108.
JACC Vol. 30, No. 5
November 1, 1997:1308–14
1308
©1997 by the American College of Cardiology 0735-1097/97/$17.00
Published by Elsevier Science Inc. PII S0735-1097(97)00315-X
clinical characteristics of the study groups are presented in
Table 1.
This study was approved by the Human Research Commit-
tee of the University of New Mexico, and all subjects gave
written, informed consent.
Echocardiography. All study subjects underwent mono-
plane (125 studies) or multiplane (102 studies) color Doppler
TEE using the model 500, 1500 or 2500 Hewlett-Packard
imaging system. In addition to standard views, careful scanning
of each heart valve was performed in multiple planes at 4- to
8-cm depth settings and with a narrow sector scan to improve
image resolution. In Group III, saline contrast studies and
complete evaluation of the thoracic aorta were performed in
57% and 86%, respectively.
The echocardiograms of the three groups were randomly
intermixed and interpreted independently by two observers
who were unaware of the clinical data. Disagreements were
resolved by a third observer.
Criteria for echocardiographic interpretation. Valve ex-
crescences were defined as thin (#2 mm) and elongated
(.3 mm) structures with independent, undulating hypermobil-
ity seen near the leaflet’s line of closure, on the atrial side of
the mitral and tricuspid valves and on the ventricular side of
the aortic valve. The mitral and tricuspid valve excrescences
were measured from the horizontal or longitudinal two-
dimensional views during systole and those of the aortic valve
from the longitudinal views during diastole. Their maximal
length and width were measured and averaged during three
cardiac cycles.
To assess intraobserver and interobserver variability in the
measurements of length and width of valve excrescences, 30
subjects (13 control subjects and 17 patients) with 37 excres-
cences (24 mitral, 9 aortic and 4 tricuspid) were randomly
selected and remeasured.
Echocardiographically normal hearts were defined as such
by standard criteria. Normal valves were those with normal
leaflet mobility and thickness (#3.0 mm mitral and #2.0 mm
aortic), without calcification and with no more than mild
regurgitation assessed by semiquantitative methods (7,8). A
valve excrescence was not considered an abnormality. Cardiac
sources of embolism were defined by established criteria
(9,10).
Clinical and echocardiographic follow-up. In the patients
in Group III, all available clinical data (history and physical
examination, neurology evaluation, imaging studies of the
brain or peripheral arteries and echocardiography) were re-
viewed to define the etiology of events as: 1) cardioembolic—
those with only a cardiac substrate for embolism (excluding
valve excrescences); 2) cardiac or vasculoembolic—those with
cardiac and thoracic aorta or carotid atheromatous disease; 3)
vasculoembolic—those with only arterial atheromatous dis-
ease; 4) nonembolic—those without cardiac or arterial disease
(including patients with suspected small-vessel disease, athero-
thrombosis or vasculitis); and 5) undetermined.
Eighty nine subjects (99%) in Group I and 84 patients
(95%) in Group II had a clinical follow-up of 58 6 21 months
or 430 person-years and 48 6 20 months or 336 person-years,
respectively, to determine the incidence of systemic embolism
by chart review and personal or telephone interview. Presum-
ing a 1% rate per year of systemic embolism in the general
population and 5% in subjects with valve excrescences (based
on a published odds ratio of 5) (2), a follow-up of 248
person-years was necessary for 80% power and alpha 0.05.
To determine whether valve excrescences persist, resolve or
appear again over time, 45 subjects in Groups I and II (32 with
and 13 without excrescences) underwent a follow-up TEE 31 6
13 (range 6 to 68) months later.
Correlation with antiphospholipid antibodies. Antiphos-
pholipid antibodies are associated with increased thrombogen-
esis, and valve excrescences are thought to have a thrombotic
pathogenesis (1,2,11,12). Because this hypothesis would be
best tested in a population with a high prevalence of antibodies
(i.e., patients with connective tissue diseases), IgG and IgM
anticardiolipin antibodies were measured at the time of initial
TEE in 47 of the 73 patients with connective tissue disease in
Group II. If we presume an association of excrescences and
antiphospholipid antibodies with an odds ratio of 3, a sample
size of 38 patients in Group II would be needed for 80% power
and alpha 0.05. We also measured antibodies in 28 subjects in
Group I, but because the prevalence of antiphospholipid
antibodies is low (,8%) in normal subjects (11), the lack of an
association can only be determined if they have a high preva-
lence of excrescences. The anticardiolipin antibodies were
measured by an enzyme-linked immunosorbent assay method
Table 1. Clinical Characteristics of Study Groups*
Group I
(normal subjects
[n 5 90])
Group II†
(SCE absent
[n 5 88])
Group III‡
(SCE present
[n 5 49])
Age (yr)
Mean 6 SD 35 6 8 44 6 11 63 6 13
Range 17–57 16–60 34–83
Female 38 (42%) 52 (59%) 7 (14%)
Male 52 (58%) 36 (41%) 42 (86%)
Hypertension 6 (7%)§ 18 (20%) 24 (49%)
Diabetes mellitus 0 2 (2%) 11 (22%)
Smoking 10 (11%) 18 (20%) 26 (53%)
Cholesterol .240 mg/dl 0 6 (7%) 15 (31%)
CAD 0 1 (1%) 16 (33%)
PVD 0 0 4 (8%)
Carotid artery disease 0 0 8 (16%)
Aspirin 2 (2%) 9 (10%) 25 (51%)
Warfarin 0 6 (7%) 11 (22%)
*p , 0.001 overall between the three groups for each clinical characteristic,
except p 5 0.02 for peripheral vascular disease. †p , 0.02 between Group II and
Group I for hypertension, smoking, elevated cholesterol and warfarin. ‡p ,
0.001 for group III versus Group I and Group III versus Group II for
hypertension, diabetes, smoking, elevated cholesterol, coronary artery disease,
carotid artery disease, aspirin and warfarin, except p 5 0.01 for peripheral
vascular disease. §These patients developed hypertension during follow-up. Data
presented are number (%) of subjects, unless otherwise indicated. CAD 5
coronary artery disease; PVD 5 peripheral vascular disease; SCE 5 suspected
cardioembolism.
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(13). The IgG and IgM antibodies were considered present
when .8 and .10 IU, respectively, were detected.
Statistical analysis. The Fisher exact test and McNemar
test were used for comparison of unpaired and paired binary
variables, respectively. The Student t test and paired t test were
used to compare unpaired and paired continuous variables,
respectively. Two-way analysis of variance was used for com-
parison of the length and width of excrescences between valves
and groups. One sample binomial test was used for comparison
of prevalence rates of valve excrescences. A p value ,0.05 was
considered significant.
Results
Characteristics of valve excrescences. Prevalence and dis-
tribution (Table 2). The prevalence of valve excrescences was
similarly high in the three study groups: 38% in Group I, 47%
in Group II and 41% in Group III. The excrescences were
equally frequent among women and men and between the
different age groups: 20 to 30 years (29%); 31 to 40 years
(46%); 41 to 50 years (48%); 51 to 60 years (37%); 61 to 70
years (33%); and 71 to 80 years (56%). Excrescences were
almost exclusively seen on the left-sided valves (92%) and
predominantly on the mitral valve (68% to 76%).
The prevalence of valve excrescences was unrelated to
aspirin or warfarin therapy. In Group II, 8 (53%) of 15 patients
taking either therapy and 33 (45%) of 73 patients taking
neither drug had valve excrescences. Similarly, in Group III, 14
(42%) of 33 patients with therapy and 6 (38%) of 16 without
therapy had valve excrescences.
Length and width. Excrescences generally measured 5 to
10 mm in length (range 4 to 16) and 1 mm in width (range 0.6
to 2) (Table 3) (Fig. 1 and 2).
Leaflet and chamber location. All but six excrescences were
seen at or very near the leaflets coaptation point, on the atrial
side during systole for the mitral (Fig. 1) and tricuspid valves
and in the outflow tract during diastole for the aortic valve
(Fig. 2). Four aortic valve excrescences were also noted on the
vessel side during systole.
Multivalvular involvement and association with valve regurgi-
tation. Excrescences were seen on more than one valve in 18%
of Group I, in 24% of Group II and in 25% of Group III. In 11
(5%) of the total 227 study subjects, more than one excres-
cence per valve was noted. In Groups I and II, #7% of valves
with and #5% without excrescences had mild regurgitation.
The rest had none or trivial regurgitation.
Evolution. Valve excrescences (23 mitral, 17 aortic and 3
tricuspid) persisted unchanged on follow-up TEE in the 32
subjects with excrescences on initial TEE. In the other 13
subjects, no excrescences were observed on either study.
Aspirin or warfarin therapy did not appear to have an effect
on the evolution of valve excrescences. Of the 32 subjects with
persistent valve excrescences, 24 (75%) were taking either
therapy between studies and 8 (25%) were not.
Association with antiphospholipid antibodies. The presence
or concentration of antiphospholipid antibodies was not asso-
ciated with the presence of excrescences. Twenty-three (49%)
of 47 patients in Group II had IgG or IgM anticardiolipin
antibodies. Thirteen (56%) of 23 patients with and 10 (44%) of
24 without excrescences had antibodies. The concentration of
IgG and IgM anticardiolipin antibodies was also similar in
subjects with (47 6 28 and 24 6 20 IU, respectively) or without
excrescences (43 6 36 and 28 6 21 IU, respectively). In Group
I, 12 (48%) of 25 subjects without antibodies had excrescences.
Cardioembolic risk. In Groups I and II, 1 (1.4%) of 74
subjects with and 2 (2%) of 99 without excrescences had
Table 3. Length and Width of Valve Excrescences
Valve
Group I Group II Group III
Length Width Length Width Length Width
Mitral (mm) 8.3 6 2.4* 1.3 6 0.4† 8.1 6 2.8 1.0 6 0.3 9.0 6 2 1.1 6 0.2
Aortic (mm) 7.0 6 2 1.1 6 0.14 8.1 6 3 1.2 6 0.4 7.0 6 1.2 1.2 6 0.2
Tricuspid (mm)‡ 7.3 6 2.5 1.25 6 0.2 8.4 6 2.6 1.0 6 0.1 — —
*p 5 0.047 for the length of mitral versus aortic valve excrescences, on average, between the three groups. In two-way
analysis of variance, the average of the three groups was used because the difference in the mean values in each group
was not different (p 5 0.13). †p 5 0.03 for the interaction between the three groups, indicating a wider width of mitral
versus aortic excrescences in Group I but a narrower width in Groups II and III. ‡Because tricuspid valve excrescences
were rare, they were not included in the analysis. Data presented are mean value 6 SD.
Table 2. Prevalence and Distribution of Valve Excrescences
Within Groups
Group I
(n 5 90)
Group II
(n 5 88)
Group III
(n 5 49)
Prevalence 34 (38%) 41 (47%) 20 (41%)
Distribution by gender
Female 13/38 (34%) 23/52 (44%) 2/7 (29%)
Male 21/52 (40%) 18/36 (50%) 18/42 (43%)
Distribution by valve
Mitral* 26 (76%) 28 (68%) 15 (75%)
Aortic 13 (38%) 18 (44%) 10 (50%)
Tricuspid 2 (6%) 4 (10%) 0
Pulmonic 0 1 (2%) 0
.1 valve 6 (18%) 10 (24%) 5 (25%)
*p , 0.001 for subjects with mitral valve excrescences compared with those
with excrescences on other valves between the three groups. p 5 0.002, 0.01 and
0.02 for Groups I, II and III, respectively. Data presented are number (%) of
subjects.
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cerebral ischemic events during a follow-up period of 53 6 22
months or 330 person-years and 53 6 20 months or 436
person-years, respectively (0.3% and 0.46% person-years, re-
spectively). The patient with an excrescence was a 26-year old
woman with systemic lupus erythematosus and hypertension in
whom a Libman-Sacks vegetation and a persistent excrescence
were seen on follow-up TEE.
Although 20 (41%) of the 49 patients in Group III had
excrescences, 85% of them had other cardiac or vascular
sources of embolism (Table 4). Also, the prevalence of excres-
cences was similar among patients with cardiac, vascular or
nonembolic events (Table 5).
Variability of measurement of valve excrescences. For one
observer, repeated measurements of 37 valve excrescences
showed a variability of up to 1.4 mm in length and 0.3 mm in
width. Between two observers, the variability was up to 1 mm
and 0.4 mm, respectively.
Discussion
Major findings. There are four important results of this
study. Valve excrescences 1) are common on the left heart
valves; 2) have a similar prevalence in normal subjects and in
patients with or without suspected cardioembolism regardless
of age and gender; 3) persist unchanged over time; and 4) do
not appear to be associated with future embolic events.
Comparison with postmortem studies. In 1856, Lambl (14)
first described small filiform processes on the ventricular
Table 4. Embolic Substrate in Patients With
Suspected Cardioembolism
Embolic Substrate
Excrescences
Present
(n 5 20)
Excrescences
Absent
(n 5 29)
LA pseudocontrast 0 5 (17%)
Patent foramen ovale 2/10* (20%) 2/16* (13%)
IA septal aneurysm 3 (15%) 1 (3%)
Valve disease 8 (40%) 7 (24%)
Low LV ejection fraction 2 (10%) 7 (24%)
Abnormal wall motion 1 (5%) 8 (28%)
LV thrombi 0 1 (3%)
LV aneurysm 0 2 (7%)
Aortic atheroma 10/20* (50%)† 3/22* (14%)
Carotid artery disease 5/13* (38%) 3/15* (20%)
Any 17 (85%)‡ 16 (55%)
*Denotes number of subjects in whom a saline contrast study, complete
evaluation of the aorta and carotid artery studies, were performed. †p 5 0.02 and
‡p 5 0.03 for subjects with versus those without excrescences. Data presented are
number (%) of subjects. IA 5 interatrial; LA 5 left atrial; LV 5 left ventricular.
Figure 1. Mitral valve excrescences in a normal 32-year old
man. This TEE closeup view of the mitral valve demon-
strates two valve excrescences (arrows) prolapsing during
systole into the left atrium (LA) from the coaptation point
of the anterior (aml) and posterior (pml) mitral leaflet.
LV 5 left ventricle.
Figure 2. Aortic valve excrescence in a 58-year old man. This TEE
longitudinal view of the aortic valve demonstrates a valve excrescence
(arrow) prolapsing during diastole into the outflow tract from the
coaptation point of the non (ncc) and right (rcc) or left coronary cusp.
aml 5 anterior mitral leaflet.
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surface of normal and abnormal aortic valves. In subsequent
pathologic series of normal valves, a 70% to 90% prevalence of
excrescences was reported, predominantly on the mitral (70%
to 85%) and aortic valves (62% to 90%), but also on the
right-sided valves (8% to 20%) (15–17). The excrescences are
thin (up to 1.5 mm in width) and elongated (up to 10 mm in
length), frequently multiple and located on the leaflet’s line of
closure, on the atrial side of the atrioventricular valves and on
the ventricular side of the semilunar valves. They are seen in
subjects 1 to 60 years old regardless of gender. Other studies of
rheumatic and degenerative valve disease report a prevalence
of 20% to 65% (18,19). Valve excrescences consist of a core of
connective tissue with collagen and elastic fibrils or of an
acellular hyaline material covered by endothelium (15–17).
Thus, it seems likely that the excrescences noted in this and
previous studies (1–4) correspond to those described by Lambl
and other investigators (14–19). Their persistence over time
without significant change supports this hypothesis. However,
surgical or pathologic studies are needed to confirm this
hypothesis.
Etiology. The etiology of valve excrescences is uncertain.
The constant bending and buckling of the leaflets may lead to
tearing of subendocardial collagen and elastic fibers, which
subsequently endothelialize (15–17). This may explain their
predominance on the left-sided valves, where the impact of
valve closure and shear forces is the highest owing to large
pressure differences. The presence of excrescences on normal
valves early in life and their similar prevalence in different age
groups suggest that they may not result from an injury or
age-related process. Finally, the lack of an association between
antiphospholipid antibodies and aspirin or warfarin therapy
does not support a relation to a hypercoagulable state.
Comparison with previous echocardiographic studies. In
this study, a higher prevalence (42%) of excrescences than that
reported in previous series (#22%) (1–4) was observed. Mitral
and aortic valve excrescences were common, but they were also
seen on the right-sided valves. Previous studies have described
them almost exclusively on the mitral (1,4) and rarely on the
aortic valve (2,3). Differences in methods may explain these
discrepant results. In this study, echocardiography was per-
formed and interpreted with emphasis on the assessment of
valve morphology, including the presence of valve excres-
cences. In previous series, echocardiography was performed
for identification of a cardioembolic substrate. This study
included excrescences with a width of #2 mm, as compared
with a recent series that included only those with a width of
#1 mm (2). Compared with previous series that have used
mostly monoplane or biplane TEE, we used multiplane TEE in
45% of subjects.
Valve excrescences as a cardioembolic substrate. In this
study of subjects with a high prevalence of valve excrescences,
the incidence of cerebrovascular ischemic events was low (,0.5
per 100 person-years) and similar to that of those without
excrescences. Also, the prevalence of excrescences was similar
in patients with and without embolic events. These findings
support the view that excrescences are neither a primary
pathogenetic factor nor a marker for embolism. Previous
studies suggesting their cardioembolic potential have several
limitations. Lee et al. (1) detected mitral valve excrescences in
11 (22%) of 50 patients with suspected cardioembolism. How-
ever, these patients were at a moderate or high risk of stroke
from other causes. Nine of the 11 patients had valve thickening
or calcification and seven had a history of arrhythmias, myo-
cardial infarction, cardiomyopathy or hypertension. Despite
presumed embolic events, 24 of the 50 patients had neither
cardiac abnormalities nor valve excrescences. Also, the mean
age of the patients was 63 years and no mention was made of
the appearance of the aorta. Freedberg et al. (2), in a
retrospective analysis of 1,559 patients with a mean age of 66
years, identified valve excrescences in 86 (5.5%). Of 597
patients with suspected embolism, 63 (10.6%) had excres-
cences, as compared with 23 (2.3%) of 962 without emboli. In
41 patients with valve excrescences but no other embolic
substrate, 33 (83%) had suspected embolism, as compared
with 12 (29%) of 41 case control subjects. Similarly, in their
group, stroke risk was high. They studied an elderly group of
patients, and .10% had prosthetic or abnormal native valves.
These factors may have contributed to their group’s high
prevalence of suspected cardioembolism (38%) and to skewing
of the results toward an association with excrescences. Prelim-
inary retrospective data in another series had similar limita-
tions (4).
Thus, currently available data have not clearly demon-
strated that valve excrescences are a source of embolism and
our data suggest they are not.
Differentiation from infective and noninfective valve
masses. Suspected cardioembolism and infective endocarditis
are among the most common indications for TEE (20). Infec-
tive vegetations have a valve distribution, leaflet and chamber
location and mobility similar to those of valve excrescences.
Although infective vegetations are generally .3 mm in diam-
eter, in patients with suspected endocarditis, it may be difficult
to differentiate a small or an early infective mass from an
excrescence. In this setting, an infective vegetation, in contrast
to an excrescence, may resolve or change in appearance over
Table 5. Prevalence of Valve Excrescences by Etiology of Stroke
or Embolism
Etiology of Event
Excrescences
Present
(n 5 20)
Excrescences
Absent
(n 5 29)
Cardioembolic 5 (25%) 12 (41%)
Cardiac or vasculoembolic* 7 (35%) 5 (17%)
Vasculoembolic 3 (15%) 0
Nonembolic† 5 (25%) 6 (21%)
Undetermined 0 6 (21%)
*Denotes the presence of cardiac and carotid or aortic atheromatous vessel
disease as sources of emboli. †Includes those with cerebral small-vessel disease,
atherothrombosis or vasculitis. Data presented are number (%) of subjects.
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time (21). Interestingly, many TEE series in infective endocar-
ditis have not reported valve excrescences as a cause of false
positive studies (22–24).
Libman-Sacks and thrombotic vegetations, in contrast to
valve excrescences, are located on any leaflet portion, are
generally rounded and sessile, measure .3 mm in diameter,
have heterogeneous echoreflectance and have no independent
mobility (25–27).
Valve excrescences are echocardiographically distinct from
ruptured chordae tendineae. Ruptured chordae tendineae are
generally .3 mm thick and associated with prolapse of the
respective leaflet, and usually the valve has myxomatous thick-
ening and significant eccentric regurgitation (28,29).
Study limitations. The lack of pathologic confirmation
limits conclusions about the nature of valve excrescences seen
on TEE. The prevalence of valve excrescences found in this
study group may differ from that of a general population.
However, the prevalence of excrescences in healthy subjects
was similar to that of two different patient groups. A larger
population with longer follow-up is necessary to better assess
the true prevalence and embolic risk of valve excrescences. An
association of excrescences with a hypercoagulable state can-
not be excluded because other variables of hypercoagulability
were not tested. However, aspirin or warfarin therapy did
not appear to have an effect on the prevalence and evolution
of valve excrescences. Also, the high prevalence of excres-
cences in healthy subjects and the lack of thromboembolic
manifestations during follow-up make this association less
likely.
Clinical implications. The results of this study have several
important clinical implications. The data are in agreement with
postmortem series establishing that valve excrescences are
frequent in subjects of any age or gender, with or without heart
disease, and are probably of no pathophysiologic significance.
Thus, the finding of valve excrescences in a patient with
suspected cardioembolism should not be considered the likely
cause of the event, and other noncardiac causes of stroke or
embolism should be investigated before recommending anti-
coagulant therapy.
Patients with suspected cardioembolism and a normal
transthoracic echocardiogram should not routinely undergo
TEE for the detection of valve excrescences. In these patients,
clinical and transthoracic echocardiographic data predict the
absence on TEE of a cardioembolic substrate in 95% of
patients (3). The detection of valve excrescences by TEE not
only does not establish a causal relation with embolism, but
also may not alter therapy.
In patients who undergo TEE for reasons other than
suspected cardioembolism, the incidental finding of a valve
excrescence probably does not warrant the prophylactic use of
antiplatelet therapy. Finally, an awareness of the high preva-
lence and distinctive characteristics of valve excrescences may
improve the diagnostic accuracy of TEE for infective and
noninfective valve masses.
We thank Clifford R. Qualls, PhD, for statistical assistance and Kristine E.
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